NCT02814500View on ClinicalTrials.gov

DP-R212 Pharmacokinetic Study Phase I

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
DRUG

DP-R212

Investigational product is prescribed to all of randomized subjects

DRUG

Amlodipine

Investigational product is prescribed to all of randomized subjects

DRUG

Rosuvastatin

Investigational product is prescribed to all of randomized subjects

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY